These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 26112988)

  • 1. Oncogenic acidic nuclear phosphoproteins ANP32C/D are novel clients of heat shock protein 90.
    Yuzefovych Y; Blasczyk R; Huyton T
    Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2338-48. PubMed ID: 26112988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
    Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
    Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
    Gallerne C; Prola A; Lemaire C
    Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.
    Guo A; Lu P; Lee J; Zhen C; Chiosis G; Wang YL
    Oncogene; 2017 Jun; 36(24):3441-3449. PubMed ID: 28114285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.
    Li HK; Matsumoto Y; Furusawa Y; Kamada T
    J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
    Usmani SZ; Bona RD; Chiosis G; Li Z
    J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
    Segawa T; Fujii Y; Tanaka A; Bando S; Okayasu R; Ohnishi K; Kubota N
    Int J Mol Med; 2014 Mar; 33(3):559-64. PubMed ID: 24366006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects.
    Chan CT; Paulmurugan R; Gheysens OS; Kim J; Chiosis G; Gambhir SS
    Cancer Res; 2008 Jan; 68(1):216-26. PubMed ID: 18172314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
    Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
    Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
    Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
    Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
    Kale Ş; Korcum AF; Dündar E; Erin N
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):253-262. PubMed ID: 31522240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
    Caldas-Lopes E; Cerchietti L; Ahn JH; Clement CC; Robles AI; Rodina A; Moulick K; Taldone T; Gozman A; Guo Y; Wu N; de Stanchina E; White J; Gross SS; Ma Y; Varticovski L; Melnick A; Chiosis G
    Proc Natl Acad Sci U S A; 2009 May; 106(20):8368-73. PubMed ID: 19416831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1.
    Lee C; Park HK; Jeong H; Lim J; Lee AJ; Cheon KY; Kim CS; Thomas AP; Bae B; Kim ND; Kim SH; Suh PG; Ryu JH; Kang BH
    J Am Chem Soc; 2015 Apr; 137(13):4358-67. PubMed ID: 25785725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.
    Nayar U; Lu P; Goldstein RL; Vider J; Ballon G; Rodina A; Taldone T; Erdjument-Bromage H; Chomet M; Blasberg R; Melnick A; Cerchietti L; Chiosis G; Wang YL; Cesarman E
    Blood; 2013 Oct; 122(16):2837-47. PubMed ID: 23943653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor-PU-H71 (NSC 750424).
    Liu M; Wang J; Wu X; Wang E; Baptista D; Scott B; Liu P
    J Pharm Biomed Anal; 2014 Feb; 89():34-41. PubMed ID: 24252723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction.
    Trendowski M
    Pharmacol Res; 2015 Sep; 99():202-16. PubMed ID: 26117427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.
    Breinig M; Mayer P; Harjung A; Goeppert B; Malz M; Penzel R; Neumann O; Hartmann A; Dienemann H; Giaccone G; Schirmacher P; Kern MA; Chiosis G; Rieker RJ
    Clin Cancer Res; 2011 Apr; 17(8):2237-49. PubMed ID: 21372220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block.
    Alfano L; Guida T; Provitera L; Vecchio G; Billaud M; Santoro M; Carlomagno F
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3552-7. PubMed ID: 20444924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.
    Moulick K; Ahn JH; Zong H; Rodina A; Cerchietti L; Gomes DaGama EM; Caldas-Lopes E; Beebe K; Perna F; Hatzi K; Vu LP; Zhao X; Zatorska D; Taldone T; Smith-Jones P; Alpaugh M; Gross SS; Pillarsetty N; Ku T; Lewis JS; Larson SM; Levine R; Erdjument-Bromage H; Guzman ML; Nimer SD; Melnick A; Neckers L; Chiosis G
    Nat Chem Biol; 2011 Sep; 7(11):818-26. PubMed ID: 21946277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE.
    Lisi L; McGuire S; Sharp A; Chiosis G; Navarra P; Feinstein DL; Dello Russo C
    J Neuroimmunol; 2013 Feb; 255(1-2):1-7. PubMed ID: 23123171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.